ScreenerHero
GUDKnight Therapeutics Inc.
TSX · CA · Healthcare · Drug Manufacturers - Specialty & Generic · knighttx.com
9.650CAD-1.73%Mkt Cap: 702.51M $P/E: 65.47

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refr…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$65.19BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
SFZN
Siegfried Holding AG
$4.01BUSDP/E 20.9
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
HIK
Hikma Pharmaceuticals PLC
$3.69BUSDP/E 12.7
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.32BUSDP/E 16.5
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap702.51M $
Enterprise Value625.63M $
Revenue (TTM)398.58M $
Gross Profit145.82M $
Net Income (TTM)-3.91M $
Revenue/Share4.029 USD
Last Price9.650 CAD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees830
CountryCA
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)65.47
P/E (Forward)37.04
PEG—
EV/EBITDA10.59
EV/Revenue1.57
P/S1.73
P/B1.18
EPS (TTM)0.15
EPS (Forward)0.26
52W Range
5.66088% of range10.17
52W High10.17 CAD
52W Low5.660 CAD
Profitability
Gross Margin44.49%
Oper. Margin6.21%
EBITDA Margin14.83%
Profit Margin-1.19%
ROE-0.70%
ROA-0.51%
Growth
Revenue Growth34.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF50.22M $
CapEx (TTM)24.54M $
FCF Margin11.58%
FCF Yield6.57%
Net Debt-63.28M $
Net Debt/EBITDA-1.07
Balance Sheet
Debt/Equity0.10
Current Ratio2.28
Quick Ratio1.45
Book Value/Sh8.130 CAD
Cash/Share1.234 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)10.83 CAD
Upside (mean)+12.2%
Target Range9.000 CAD – 12.00 CAD
CAD9.000+12.2% to meanCAD12.00
# Analysts7
Ownership
Shares Out.98.23M
Float60.29M
Insiders46.99%
Institutions18.12%
Short Interest
Short Ratio11.4d
Short % Out.1.28%
Shares Short1.43M
Short (prev mo.)1.42M
Technical
SMA 509.620 (+0.3%)
SMA 2007.445 (+29.6%)
Beta0.05
S&P 52W Chg18.16%
Avg Vol (30d)108.56K
Avg Vol (10d)95.69K
Technical Indicators
RSI (14)56.0
MACD-0.0348
MACD Signal-0.0089
MACD Hist.-0.0259
BB Upper10.11 CAD
BB Middle9.618 CAD
BB Lower9.121 CAD
BB Width10.33%
ATR (14)0.3029 CAD
Vol Ratio (20d)0.57x